Fig. 2From: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse modelValidation of in vitro oncolytic adenoviral replication efficiency and the expression patterns of the encoded TRAIL and IL-12 transgenes in human HCC cells. HuH7 cells were cultured and then treated with PBS, Ad-ΔB, or Ad-ΔB/TRAIL+ Ad-ΔB/IL-12 at a MOI of 5 for each virus. Two days post-treatment, the cell lysates and conditioned media were harvested and relative mRNA and protein levels of TRAIL (a and b), or IL-12 (c and d) were measured by using Q-RT-PCR and ELISA assays, respectively. Data are represented as mean ± SE. In addition, viral production was determined by measuring the expression of Ad E1A protein (e) by western blot assay using rabbit anti-Ad E1A primary antibodyBack to article page